Senti Biosciences, Inc.
A clinical-stage biotechnology company developing next-generation cell and gene therapies using gene circuit platform technology. The company is conducting clinical trials of chimeric antigen receptor natural killer (CAR-NK) cell therapies for acute myeloid leukemia and other hematological malignancies, hepatocellular carcinoma and other solid tumors. Based in Delaware.
Overview
Overview | |
|---|---|
Country | United States |
State | California |
Employees | 48 |
Founded | 2016 |
Financials | |
|---|---|
Market Capitalization | 14.64M |
Revenue | 1.27M |
Operating Income | -98.51M |
Operating Margin | -7726.27% |
Net Income | -64.45M |
Ranking
Operating Income
Operating Income Ranking | |
|---|---|
All | 4774 / 5373 |
Sector : Healthcare | 874 / 1144 |
Industry : Biotechnology | 444 / 645 |
Market Capitalization
Market Capitalization Ranking | |
|---|---|
All | 5060 / 5565 |
Sector : Healthcare | 987 / 1182 |
Industry : Biotechnology | 553 / 670 |
Net Income
Net Income Ranking | |
|---|---|
All | 4501 / 5436 |
Sector : Healthcare | 787 / 1164 |
Industry : Biotechnology | 383 / 659 |
Employees
Employees Ranking | |
|---|---|
All | 4457 / 5330 |
Sector : Healthcare | 815 / 1174 |
Industry : Biotechnology | 383 / 667 |